Literature DB >> 12897145

Mouse mammary tumor virus c-rel transgenic mice develop mammary tumors.

Raphaëlle Romieu-Mourez1, Dong W Kim, Sang Min Shin, Elizabeth G Demicco, Esther Landesman-Bollag, David C Seldin, Robert D Cardiff, Gail E Sonenshein.   

Abstract

Amplification, overexpression, or rearrangement of the c-rel gene, encoding the c-Rel NF-kappaB subunit, has been reported in solid and hematopoietic malignancies. For example, many primary human breast cancer tissue samples express high levels of nuclear c-Rel. While the Rev-T oncogene v-rel causes tumors in birds, the ability of c-Rel to transform in vivo has not been demonstrated. To directly test the role of c-Rel in breast tumorigenesis, mice were generated in which overexpression of mouse c-rel cDNA was driven by the hormone-responsive mouse mammary tumor virus long terminal repeat (MMTV-LTR) promoter, and four founder lines identified. In the first cycle of pregnancy, the expression of transgenic c-rel mRNA was observed, and levels of c-Rel protein were increased in the mammary gland. Importantly, 31.6% of mice developed one or more mammary tumors at an average age of 19.9 months. Mammary tumors were of diverse histology and expressed increased levels of nuclear NF-kappaB. Analysis of the composition of NF-kappaB complexes in the tumors revealed aberrant nuclear expression of multiple subunits, including c-Rel, p50, p52, RelA, RelB, and the Bcl-3 protein, as observed previously in human primary breast cancers. Expression of the cancer-related NF-kappaB target genes cyclin D1, c-myc, and bcl-xl was significantly increased in grossly normal transgenic mammary glands starting the first cycle of pregnancy and increased further in mammary carcinomas compared to mammary glands from wild-type mice or virgin transgenic mice. In transient transfection analysis in untransformed breast epithelial cells, c-Rel-p52 or -p50 heterodimers either potently or modestly induced cyclin D1 promoter activity, respectively. Lastly, stable overexpression of c-Rel resulted in increased cyclin D1 and NF-kappaB p52 and p50 subunit protein levels. These results indicate for the first time that dysregulated expression of c-Rel, as observed in breast cancers, is capable of contributing to mammary tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12897145      PMCID: PMC166341          DOI: 10.1128/MCB.23.16.5738-5754.2003

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  69 in total

1.  NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1.

Authors:  D C Guttridge; C Albanese; J Y Reuther; R G Pestell; A S Baldwin
Journal:  Mol Cell Biol       Date:  1999-08       Impact factor: 4.272

2.  Nuclear factor-kappaB/Rel blocks transforming growth factor beta1-induced apoptosis of murine hepatocyte cell lines.

Authors:  M Arsura; M J FitzGerald; N Fausto; G E Sonenshein
Journal:  Cell Growth Differ       Date:  1997-10

3.  Oncogenic Ha-Ras-induced signaling activates NF-kappaB transcriptional activity, which is required for cellular transformation.

Authors:  T S Finco; J K Westwick; J L Norris; A A Beg; C J Der; A S Baldwin
Journal:  J Biol Chem       Date:  1997-09-26       Impact factor: 5.157

4.  NF-kappaB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition.

Authors:  M Hinz; D Krappmann; A Eichten; A Heder; C Scheidereit; M Strauss
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

5.  The inhibitory effects of transforming growth factor beta1 on breast cancer cell proliferation are mediated through regulation of aberrant nuclear factor-kappaB/Rel expression.

Authors:  M A Sovak; M Arsura; G Zanieski; K T Kavanagh; G E Sonenshein
Journal:  Cell Growth Differ       Date:  1999-08

6.  Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer.

Authors:  M A Sovak; R E Bellas; D W Kim; G J Zanieski; A E Rogers; A M Traish; G E Sonenshein
Journal:  J Clin Invest       Date:  1997-12-15       Impact factor: 14.808

7.  The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis.

Authors:  W X Zong; L C Edelstein; C Chen; J Bash; C Gélinas
Journal:  Genes Dev       Date:  1999-02-15       Impact factor: 11.361

8.  Bcl-x protects primary B cells against Fas-mediated apoptosis.

Authors:  T J Schneider; D Grillot; L C Foote; G E Núñez; T L Rothstein
Journal:  J Immunol       Date:  1997-11-15       Impact factor: 5.422

9.  Overexpression of Bcl-2 inhibits alveolar cell apoptosis during involution and accelerates c-myc-induced tumorigenesis of the mammary gland in transgenic mice.

Authors:  R Jäger; U Herzer; J Schenkel; H Weiher
Journal:  Oncogene       Date:  1997-10-09       Impact factor: 9.867

10.  An essential role for nuclear factor kappa B in preventing TNF-alpha-induced cell death in prostate cancer cells.

Authors:  M Sumitomo; M Tachibana; J Nakashima; M Murai; A Miyajima; F Kimura; M Hayakawa; H Nakamura
Journal:  J Urol       Date:  1999-02       Impact factor: 7.450

View more
  44 in total

1.  NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression.

Authors:  Margit A Huber; Ninel Azoitei; Bernd Baumann; Stefan Grünert; Andreas Sommer; Hubert Pehamberger; Norbert Kraut; Hartmut Beug; Thomas Wirth
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

2.  Activation of NF-kappaB in bone marrow cells of BALB/cJ mice following exposure in vivo to low doses of (137)Cs gamma-rays.

Authors:  Kanokporn Noy Rithidech; Montree Tungjai; Edgar Arbab; Sanford R Simon
Journal:  Radiat Environ Biophys       Date:  2005-11-02       Impact factor: 1.925

3.  Regulation of p53 tumour suppressor target gene expression by the p52 NF-kappaB subunit.

Authors:  Katie Schumm; Sonia Rocha; Jorge Caamano; Neil D Perkins
Journal:  EMBO J       Date:  2006-09-21       Impact factor: 11.598

4.  c-Rel downregulation affects cell cycle progression of human keratinocytes.

Authors:  Verena N Lorenz; Michael P Schön; Cornelia S Seitz
Journal:  J Invest Dermatol       Date:  2013-07-26       Impact factor: 8.551

5.  CAPERalpha is a novel Rel-TAD-interacting factor that inhibits lymphocyte transformation by the potent Rel/NF-kappaB oncoprotein v-Rel.

Authors:  Jui Dutta; Gaofeng Fan; Céline Gélinas
Journal:  J Virol       Date:  2008-08-27       Impact factor: 5.103

6.  The p53 homologue DeltaNp63alpha interacts with the nuclear factor-kappaB pathway to modulate epithelial cell growth.

Authors:  Kathryn E King; Roshini M Ponnamperuma; Clint Allen; Hai Lu; Praveen Duggal; Zhong Chen; Carter Van Waes; Wendy C Weinberg
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

7.  Survival and differentiation of mammary epithelial cells in mammary gland development require nuclear retention of Id2 due to RANK signaling.

Authors:  Nam-Shik Kim; Hyoung-Tai Kim; Min-Chul Kwon; Suk-Won Choi; Yoon-Young Kim; Ki-Jun Yoon; Bon-Kyoung Koo; Myung-Phil Kong; Juhee Shin; Yunje Cho; Young-Yun Kong
Journal:  Mol Cell Biol       Date:  2011-09-26       Impact factor: 4.272

8.  Gene expression profiling in sinonasal adenocarcinoma.

Authors:  Dominique Tripodi; Sylvia Quéméner; Karine Renaudin; Christophe Ferron; Olivier Malard; Isabelle Guisle-Marsollier; Véronique Sébille-Rivain; Christian Verger; Christian Géraut; Catherine Gratas-Rabbia-Ré
Journal:  BMC Med Genomics       Date:  2009-11-10       Impact factor: 3.063

Review 9.  Galectin-4 in normal tissues and cancer.

Authors:  Margaret E Huflejt; Hakon Leffler
Journal:  Glycoconj J       Date:  2004       Impact factor: 2.916

10.  Stimulation of c-Rel transcriptional activity by PKA catalytic subunit beta.

Authors:  Shih-Hung Yu; Wei-Chung Chiang; Hsiu-Ming Shih; Kou-Juey Wu
Journal:  J Mol Med (Berl)       Date:  2004-06-09       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.